Concert Pharmaceuticals (CNCE) Given a $34.00 Price Target by UBS Group Analysts

Concert Pharmaceuticals (CNCE) Given a $34.00 Price Target by UBS Group Analysts

Concert Pharmaceuticals (NASDAQ:CNCE) received a $34.00 price target from stock analysts at UBS Group in a research note issued to investors on … Receive News & Ratings for Concert Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news
See Original Article

HC Wainwright Has Just Reaffirmed $21.0 Target Price Per Share on Concert Pharma (NASDAQ …

More interesting news about Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) were released by: Businesswire.com and their article: “Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index” published on December 13, 2017 as well as Seekingalpha.com's news article titled: “Conc
See Original Article

Choir's church concert for Macmillan cause

The Stamford Bridge Community Choir members could see their breath in the cold at the church. Published: 10:09 Saturday 30 December 2017. Stamford Bridge Community Choir recently performed its Community Carols event at Low Catton Church. The choir members, who could see their breath in
See Original Article

UBS Group Reiterates “$34.00” Price Target for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ:CNCE) has been given a $34.00 price target by UBS Group in a note issued to investors on Tuesday, December … Receive News & Ratings for Concert Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and
See Original Article

Please follow and like us:
Facebook
Facebook
TWITTER
Visit Us
INSTAGRAM